Collegium Provides 2026 Financial Guidance and Business Update

Core Insights - Collegium Pharmaceutical, Inc. has announced its financial guidance for 2026, projecting product revenues between $805 million and $825 million, with Jornay PM net revenue expected to be between $190 million and $200 million, and adjusted EBITDA anticipated in the range of $455 million to $475 million [1][4][5] Financial Performance - The company reported record growth in 2025, driven by strong performance in Jornay PM and sustained revenue growth across its pain management portfolio [2][5] - The financial guidance for 2025 was raised to a net revenue range of $775 million to $785 million and adjusted EBITDA between $460 million and $470 million, with results expected to be reported in February 2026 [5] Business Development - Collegium has successfully closed a $980 million syndicated credit facility, which will be used to repay a previous term loan and provide capital for future business development opportunities [5] - The company has entered into agreements with Hikma Pharmaceuticals for the authorized generic versions of Nucynta and Nucynta ER, with expected launches in 2026 [5] Strategic Focus - Collegium aims to balance capital deployment by paying down debt, repurchasing shares, and exploring opportunities to expand and diversify its portfolio [2][5] - The company is committed to improving the lives of patients with serious medical conditions through its diversified biopharmaceutical portfolio [5][6]